O12-4 Clinical significance of comprehensive genomic profiling in pediatric cancer patients

Abstract

Since June 2019, gene alterations in patients (pts) with advanced solid cancers are screened on comprehensive genomic profiling (CGP) tests, which is covered by the national health insurance system in Japan. Although most of the molecular-targeted drugs corresponding to the actionable genes alterations in solid cancers are off-labeled in pediatric pts, their therapeutic efficacy may be superior to conventional anticancer drugs.